FDA approves Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to neovascular or ‘wet’ age-related macular degeneration and diabetic macular edema Approval is based on two phase III studies demonstrating early and sustained vision improvements that were non-inferior to aflibercept Vabysmo also demonstrated rapid and robust drying of retinal fluid Additional U.S. label update across indications […]
Positive topline phase III results show Roche's Vabysmo improved vision for people living with retinal vein occlusion (RVO)
Vabysmo achieved its primary endpoint of non-inferiority to aflibercept in RVO in the BALATON and COMINO clinical trials Vabysmo was generally well tolerated, with a safety profile consistent with previous trials Vabysmo is the first and only treatment that targets and inhibits two disease pathways involving Ang-2 and VEGF-A, linked to a number of vision-threatening […]
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two years Initiation of OCREVUS as first-line treatment reduces relapses, hospitalisations and costs compared with using OCREVUS in second-line setting Nine-year long-term safety data for OCREVUS further reinforce favourable benefit-risk profile; more than […]
WHO calls for immediate release, access to, and medical support for hostages taken by Hamas
Gravely concerned by the humanitarian and health situation facing approximately 200 people, including health workers and up to 30 children, abducted from Israel by Hamas and other armed groups on 7 October 2023, the World Health Organization (WHO) today reiterated its call for the immediate release of all the hostages, along with urgent access to […]
Shock, grief and the challenge of healing: Israel’s health system responds to the October attacks
Dr Michel Thieren, WHO Special Representative in Israel, spent almost 2 weeks travelling across the country to see how the health system is responding in the aftermath of the attacks led by Hamas on 7 October. This is his account of what he saw and heard. Note: Some readers may find the content of this […]
Roche’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC) With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for […]
Roche IL-6 is the first immunoassay approved to aid sepsis diagnosis in newborns
Neonatal sepsis is a leading cause of death for newborns Testing IL-6 can indicate a neonatal sepsis infection earlier than other biomarkers Earlier diagnosis of neonatal sepsis can lead to improved outcomes and a reduction of long-term complications from sepsis Basel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the […]
UNICEF and WHO warn that further attacks and disruptions of health and nutrition services in Sudan could cost over 10 000 young lives by the end of 2023
6 months of conflict in Sudan leave millions of children at risk of cholera, dengue, measles, malaria and other diseases without sufficient containment capacities 18 October 2023, Port Sudan, Sudan – Since the outbreak of the conflict in Sudan on 15 April 2023, UNICEF, WHO and partners have been supporting the Federal Ministry of Health […]
Union Health Secretary Shri Sudhansh Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface” & National Conclave for Endorsement of “National Action Plan for Prevention and Control of Snakebite Envenoming” to Stakeholders
“Zoonotic disease is one of the areas of concern which is affecting the humans as well as the animal health. 75% of newly emerging infectious diseases that have affected people over last three decades are zoonotic in nature. The limited knowledge and skill to identify zoonotic diseases, coupled with limited diagnostic facilities at all levels […]
Roche’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeks OCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeks The safety profile […]
